Communicators

are winners!

News

21.12.2020
Medigene AG: Participation at upcoming virtual conferences

 

Planegg/Martinsried (21.12.2020) - 21 December 2020. Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, will participate at the following upcoming scientific and investor conferences. Please note that all mentioned conferences will be conducted virtually due to COVID-19 pandemic.

 

LifeSci Advisors Corporate Access Event

6 -8 and 11 - 14 January 2021

https://www.meetmax.com/sched/event_68227/conference_home.html

 

TCT | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

8 -12 February 2021

https://na.eventscloud.com/ehome/557487/1068061/?&t=a1841bb4129a83843cd064f3a0d9aa8d

 

CAR-TCR Europe

16 -18 February 2021

https://cartcr-europe.com/?gclid=EAIaIQobChMIiK26pMff7QIVSAwGAB15vAsWEAAYASAAEgL0rPD_BwE

 

Immuno-Oncology 360°

23 -26 February 2021

https://theconferenceforum.org/conferences/immuno-oncology-360/overview/

 

About Medigene

 

Medigene AG (FSE: MDG1, Prime Standard, ISIN DE000A1X3W00) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

 

For more information, please visit www.medigene.com

 

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

 

Medigene

Dr. Gary Waanders, Dr. Anna Niedl

Phone: +49 89 2000 3333 01

e-mail: investor@medigene.com

 

LifeSci Advisors

Mary-Ann Chang

Phone: +44 7483 284 853

e-mail: mchang@lifesciadvisors.com

 

(end)

 

emitter: Medigene AG

address: Lochhamer Straße 11, 82152 Planegg/Martinsried

country: Germany

contact person: Medigene PR/IR

phone: +49 89 2000 3333 01

e-mail: investor@medigene.com

website: www.medigene.com

 

ISIN(s): DE000A1X3W00 (share)

stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf, free market in Hannover; open market in Berlin, Tradegate

 



NEWSLETTER REGISTRIERUNG:



Aktuelle Pressemeldungen dieses Unternehmens direkt in Ihr Postfach:
Newsletter...

Mitteilung übermittelt durch IRW-Press.com. Für den Inhalt ist der Aussender verantwortlich.

Kostenloser Abdruck mit Quellenangabe erlaubt.